5-6 December 2018

London, UK

The Tumor Models Conference Series is dedicated to exploring the latest advances in the application of preclinical models to enhance the translation of cancer therapies from bench to patient.

Merging its unique strategic focus and scientific quality of presentations, the event facilitates an environment of knowledge sharing and debate to actively assess how the industry is overcoming challenges in drug development through the use of in vitro & in vivo models.

As 2018 comes to a close, make sure you don’t miss out on the most trusted and assured meeting dedicated to helping you predict the clinical outcome of your drug candidates more accurately.

CHECK OUT THIS YEARS AGENDA HERE:

 

3 Top Highlights from Tumour Models 2017:

  1. Novartis’ Head of Drug Discovery & Pharmacology demonstrating how forward genetics in-vivo screens enabled the discovery of resistance mechanisms to a novel HDM2/p53 inhibitor and led to further clinical combination treatments

  2. Merck’s Head Cancer Stem Cells revealing the utility of novel 3D tumouroids in detailing how the TME & CSC-niche governs tumour plasticity and affects drug combination efficacy/response

  3. Genmab’s Principle TR&P Scientist highlights the value of PDX co-trials as a more predictive tool for assessing clinical response and identifying predicable patient-relatable biomarker signature

 

PART OF TUMOR MODELS SERIES

Tumor models SF logo   Tumor Models Boston Logo no year